249 related articles for article (PubMed ID: 35444666)
21. Relative efficacy and safety of calcineurin inhibitor, mycophenolate mofetil, and azathioprine as maintenance therapies for lupus nephritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):140-147. PubMed ID: 37278824
[TBL] [Abstract][Full Text] [Related]
22. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.
Jiang YP; Zhao XX; Chen RR; Xu ZH; Wen CP; Yu J
Medicine (Baltimore); 2020 Sep; 99(38):e22328. PubMed ID: 32957400
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of tacrolimus versus mycophenolate mofetil as induction treatment and low-dose tacrolimus as treatment for lupus nephritis: a meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Nov; 82(9):754-762. PubMed ID: 36607421
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis.
Zhou T; Lin S; Yang S; Lin W
Drug Des Devel Ther; 2019; 13():857-869. PubMed ID: 30880918
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.
Kamanamool N; McEvoy M; Attia J; Ingsathit A; Ngamjanyaporn P; Thakkinstian A
Medicine (Baltimore); 2010 Jul; 89(4):227-235. PubMed ID: 20616662
[TBL] [Abstract][Full Text] [Related]
28. Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2022 Oct; 31(12):1468-1476. PubMed ID: 35986446
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study.
Goswami RP; Sircar G; Sit H; Ghosh A; Ghosh P
J Clin Rheumatol; 2019 Jan; 25(1):28-35. PubMed ID: 29561474
[TBL] [Abstract][Full Text] [Related]
30. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
[TBL] [Abstract][Full Text] [Related]
31. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
Lee YH; Woo JH; Choi SJ; Ji JD; Song GG
Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907
[TBL] [Abstract][Full Text] [Related]
32. Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis.
Kawazoe M; Nanki T
Lupus; 2024 Apr; 33(4):319-327. PubMed ID: 38232223
[TBL] [Abstract][Full Text] [Related]
33. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O
Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
[TBL] [Abstract][Full Text] [Related]
35. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
36. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China.
Kim S; Reen Ooi AY; Stephens T; Jiang H
J Comp Eff Res; 2019 Oct; 8(13):1125-1141. PubMed ID: 31580156
[No Abstract] [Full Text] [Related]
38. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.
Liu LL; Jiang Y; Wang LN; Yao L; Li ZL
Drugs; 2012 Jul; 72(11):1521-33. PubMed ID: 22818016
[TBL] [Abstract][Full Text] [Related]
39. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
